CLINICAL TRIALS AND OBSERVATIONS Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
نویسندگان
چکیده
1Department of Hematology and Regional Tumor Registry, Lund University Hospital, Lund; 2Department of Hematology and Regional Tumor Registry, Linköping University Hospital, Linköping; 3Center of Hematology and Regional Tumor Registry, Karolinska University Hospital, Stockholm; 4Department of Hematology, Karolinska University Hospital, Huddinge; 5Department of Medicine and Regional Tumor Registry, Sahlgrenska University Hospital, Göteborg; 6Department of Medicine, Örebro University Hospital, Örebro; 7Department of Medicine and Regional Tumor Registry, Norrland University Hospital, Umeå; 8Department of Hematology and Regional Tumor Registry, Academic Hospital, Uppsala, Sweden; and 9Swedish Acute Myeloid Leukemia Registry Group
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007
Since 2001, the World Health Organization classification for hematopoietic and lymphoid neoplasms has provided a framework for defining acute leukemia (AL) subtypes, although few populationbased studies have assessed incidence patterns and patient survival accordingly. We assessed AL incidence rates (IRs), IR ratios (IRRs), and relative survival in the United States (2001-2007) in one of the fi...
متن کاملCLINICAL TRIALS AND OBSERVATIONS A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
Older patients with acute myeloid leukemia (AML) have limited treatment options and a poor prognosis, thereby warranting novel therapeutic strategies. We evaluated the efficacy of lenalidomide as frontline therapy for older AML patients. In this phase 2 study, patients 60 years of age or older with untreated AML received highdose (HD) lenalidomide at 50 mg daily for up to 2 28-day cycles. If pa...
متن کاملAzacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group
We recently published a clinically-meaningful improvement in median overall survival (OS) for patients with acute myeloid leukaemia (AML), >30% bone marrow (BM) blasts and white blood cell (WBC) count ≤15 G/L, treated with front-line azacitidine versus conventional care regimens within a phase 3 clinical trial (AZA-AML-001; NCT01074047; registered: February 2010). As results obtained in clinica...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia
1Pediatric Hematology and Oncology, University of Frankfurt, Germany; 2Department of Pediatric Hematology and Oncology, Hannover Medical School, Germany; 3Children’s Cancer Research Institute, St Anna Kinderspital and Children’s Cancer Research Institute (CCRI), Vienna, Austria; 42nd Medical School, Charles University, Prague, Czech Republic; 5Department of Pediatric Hematology and Oncology, Un...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia
Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia Sarah Bertoli, Emilie Bérard, Françoise Huguet, Anne Huynh, Suzanne Tavitian, François Vergez, Sophie Dobbelstein, Nicole Dastugue, Véronique Mansat-De Mas, Eric Delabesse, Eliane Duchayne, Cécile Demur, Audrey Sarry, Valérie Lauwers-Cances, Guy Laurent, Michel ...
متن کامل